Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

NCT03896724 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

450

Enrollment

OTHER

Sponsor class

Conditions

Malaria,Falciparum

Interventions

BIOLOGICAL: R21 adjuvanted with 25mcg Matrix-M
BIOLOGICAL: Rabies Vaccine
BIOLOGICAL: R21 adjuvanted with 50mcg Matrix-M

Sponsor

University of Oxford

Collaborators

[object Object]
[object Object]